Online inquiry

IVTScrip™ mRNA-Anti-CD52, GZ-402668(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8009MR)

This product GTTS-WQ8009MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD52 gene. The antibody can be applied in Multiple sclerosis (MS) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_001803.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1043
UniProt ID P31358
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD52, GZ-402668(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8009MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ1275MR IVTScrip™ mRNA-Anti-EGFR, ABT-414(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABT-414
GTTS-WQ12074MR IVTScrip™ mRNA-Anti-CD19, MOR-00208(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MOR-00208
GTTS-WQ12800MR IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA OMP-59R5
GTTS-WQ14916MR IVTScrip™ mRNA-Anti-stx1B, Shigamabs®(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ8590MR IVTScrip™ mRNA-Anti-FOLH1, HuJ591-DOTA(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HuJ591-DOTA
GTTS-WQ1003MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-383(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-383
GTTS-WQ5178MR IVTScrip™ mRNA-Anti-IL13, CAT-354(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CAT-354
GTTS-WQ12601MR IVTScrip™ mRNA-Anti-F11, NVS250519(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA NVS250519
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW